A Study of GSK3511294 in Participants With Severe Asthma With an Eosinophilic Phenotype
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Asthma
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Participants will be randomized in a 2:1 ratio to receive either GSK3511294 or placebo as an adjunct therapy.Masking: Double (Participant, Investigator)Masking Description: This will be a double blind study.Primary Purpose: Treatment
Participation Requirements
- Age
- Between 12 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04718103
- Collaborators
- Iqvia Pty Ltd
- Investigators
- Study Director: GSK Clinical Trials GlaxoSmithKline
Get Well Soon